Alterity Therapeutics Ltd. · ASX:ATH

Alterity Therapeutics — Shareholder Meeting (November 2026)

16 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 20, 2026

  1. Slide 1: Chairman's Address 2026 Annual General Meeting

    For personal use only Chairman’s Address 2026 Annual General Meeting Good morning, ladies and gentlemen, and welcome to Alterity Therapeutics' 2026 Annual General Meeting. For those I haven't had the opportunity to meet, my name is Julian Babarczy, and I am the Chairman of Alterity. This is my first

  2. Slide 2: Chairman's Address (continued)

    Alongside the regulatory progress, we have continued to build our scientific evidence base. Further analyses of our Phase 2 results, together with publications and presentations at major international scientific conferences, have strengthened our understanding of ATH434 and helped inform the design

  3. Slide 3: Chairman's Address (continued)

    We finished September with A$41.3 million in cash, providing an important financial foundation as we advance our preparations. However, Phase 3 will require a substantial financial commitment, and securing the appropriate funding and development structure remains a key priority for the Board. We con

  4. Slide 4: About Alterity Therapeutics Limited

    About Alterity Therapeutics Limited For personal use only Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson’s dise

  5. Slide 5: Annual General Meeting November 2026

    rsonal use only Annual General Meeting 20 November 2026

  6. Slide 6: Forward looking statements

    Forward looking statements This presentation should be read in conjunction with the risk factors disclosed in Alterity Therapeutics Limited’s most recent filings with the Australian Securities Exchange and the United States Securities and Exchange Commission, including the Company’s most recent Annu

  7. Slide 7: Redefining Neurodegenerative Disease Therapy

    Redefining Neurodegenerative Disease Therapy ATH434: Potential First-in-Class, Disease-Modifying Therapy for Multiple System Atrophy (MSA) Compelling Phase 2 Efficacy on Unmet Need with Significant 1 2 rsonal use only FDA-Endorsed Endpoint Commercial Potential – Up to 46% slowing of disease progress

  8. Slide 8: We delivered on the three objectives we set for 2026

    We delivered on the three objectives we set for 2026 WHAT WE DID rsonal use only OBJECTIVE Two Type C meetings and an End-of-Phase 2 meeting. FDA agreed 1 Finalize the regulatory strategy to initiate Phase 3 in MSA on key elements of the Phase 3 design and that one pivotal trial plus confirmatory ev

  9. Slide 9: Every quarter of FY26 delivered key milestones

    Every quarter of FY26 delivered key milestones Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 rsonal use only Jul – Sep 2025 Oct – Dec 2025 Jan – Mar 2026 Apr – Jun 2026 Jul Positive topline data Oct Oral platform Jan Shareholder letter set Apr Positive FDA Type C from ATH434-202 presentation and two three CY2026

  10. Slide 10: Our treatment approach: Address underlying pathology

    Our treatment approach: Address underlying pathology Increased Brain Iron in Areas of Pathology Break the Vicious Cycle rsonal use only Multiple System Atrophy Putamen (M) n=8 * n = 10 Putamen (L) n=8 n=8 n=8 Globus pallidus (M) n=9 Key drivers of Globus pallidus (L) n=8 n = 11 * pathology n=6 * S.

  11. Slide 11: Multiple data analyses strengthened the understanding of ATH434 mechanism

    Multiple data analyses strengthened the understanding of ATH434 mechanism and provide a clear path to Phase 3 – 46–52% slowing of functional decline on UMSARS Part I across ATH434 breaks the link between iron CLINICAL EFFICACY analyses, well above the clinically meaningful threshold accumulation and

  12. Slide 12: FDA engagement secured alignment on key elements of the Phase 3 program

    FDA engagement secured alignment on key elements of the Phase 3 program MARCH 2026 What the FDA agreed at End-of-Phase 2 rsonal use only Type C meeting Clinical pharmacology and non-clinical Single pivotal trial plus confirmatory evidence could support plans supported Pathway approval ~200 patients

  13. Slide 13: New patent extends the life of ATH434

    New patent extends the life of ATH434 NEW U.S. COMPOSITION OF MATTER PATENT EXPANDING BEYOND MSA rsonal use only Parkinson’s disease now a viable target 2045 indication The strengthened IP provides the protection needed to justify future Protection for ATH434 to 2045 investment in Parkinson’s diseas

  14. Slide 14: Independent research and physician feedback point to a significant opportunity

    Independent research and physician feedback point to a significant opportunity for ATH434 in MSA Independent Commercial Assessment rsonal use only >70% of surveyed neurologists “extremely likely” or “very US$2.4B likely” to prescribe ATH434 based on its profile Potential worldwide annual peak sales

  15. Slide 15: Positioned for Success

    Positioned for Success REGULATORY rsonal use only PHASE 3 READINESS MILESTONES BUILDING VALUE • FDA alignment on Phase 3 • Initiated trial start-up activities • New U.S. composition of study design • Finalize protocol matter patent granted for • Type C alignment on clinical ATH434 with protection to

  16. Slide 16: rsonal use only

    rsonal use only ASX: ATH NASDAQ: ATHE

Alterity Therapeutics — Shareholder Meeting (November 2026) on 6ix